Pharmafile Logo

preladenant

Merck’s new insomnia drug clears phase III trial

Novel method of treatment offers fewer side effects

- PMLiVE

Lilly’s poor run continues as Alimta fails in lung cancer

Phase III trial comparing it to Roche's Avastin misses primary endpoint

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links